Medshine Discovery Inc.
79 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Aug 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor (US 11,655,248) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 2 fees due Dec 13 to 20, 2026 · next Dec 13
- 2 fees due Jan 4 to 18, 2027 · next Jan 4
- 1 fee due May 14, 2027The maintenance fee for Heterocyclic compound (US 11,814,371) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Bicyclic compound that acts as CRBN protein regulator (US 11,905,276) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases (US 10,604,513) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,280,229 | Linkers and their application towards ADC In force · From the USPTO record | In force | From the USPTO record | |
| US 10,183,915 | Axially Chiral Isomers, and Preparation Methods Therefor and Pharmaceutical Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,717,720 | Modified compound of andrographolide In force · From the USPTO record | In force | From the USPTO record | |
| US 10,604,513 | Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,662,189 | PDE4 inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,040,984 | Quinazoline compound for EGFR inhibition In force · From the USPTO record | In force | From the USPTO record | |
| US 11,466,024 | Bicylic compound acting as an inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,198,686 | Crystal form and salt form of pyridone compound and preparation method therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,572,372 | Anti-hbvtetrahydroisoxazolo[4,3-c]pyridine Compounds In force · High confidence | In force | High confidence | |
| US 11,623,923 | Uracil compound as c-MET/AXL inhibitor In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 36: 79 patents in force now held by others · 14 lapsed for an unpaid fee · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
24 pending · 4 abandoned · 40 no status recorded